At a glance
ClinicalIndex Comparison RecordN/ACompleted· 163 enrolled
Drug / intervention
Hydroxyureadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Study
National Heart, Lung, and Blood Institute (NHLBI)·observational·Posted Apr 29, 2009·Updated Aug 20, 2020
In Brief
An observational study evaluating Hydroxyurea for Anemia, Sickle Cell. Completed, enrolled 163 participants across 14 sites.
Detailed Summary
Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA. The purpose of this follow-up study is to evaluate the long-term effects of hydroxyurea in children who have participated in the BABY HUG study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedApr 2009
Primary CompletionDec 2011
TodayJul 2026
First PostedApr 29, 2009
Enrollment StartSep 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.2 years ago
Interventions
Hydroxyureadrug
Parents and child's doctor may plan to use or not to use hydroxyurea.